Animal Pharm's Top Tier Companies: 2007 edition

• Analyse recent merger and acquisition activity in the sector including the impact of the pending takeover of Intervet by Schering Plough on the market.
• Examine factors affecting market growth rates and look at the bigger picture.
• Assess company sales rankings for 2006 and going back to 2001 as well as forecasts for 2007data to help you prepare for.
• Review the size, structure and recent development of the global market to aid your future planning and strategy.
• Invest in this report to keep informed of the performance of your potential competitors, collaborators or customers.

• The ultimate guide to the animal health industry and its major players is updated and improved for 2007. With 26 company profiles included to further enhance your competitor intelligence.
• In-depth company profiles are given for the top 12 animal health companies and a further 14 second tier companies.

• Merger and acquisition deals have concentrated shares of the market increasingly in the hands of a few leading players and have resulted in a clearer split between ownership of interests in the ‘medicinal’ and ‘nutritional’ segments of the industry.
• The report is tightly focused on the core animal health market-a definition that spans veterinary pharmaceuticals, biologicals and medicinal feed additives and excludes pure animal nutrition businesses.
• Defined along those lines, the global market for animal health products was worth almost US$18.6 billion in 2006.

CHAPTER 1 INTRODUCTION

1.1 The world market for animal health products

1.1.1 Market shares by region

1.1.2 Market shares by product category

1.1.3 Market shares by species

1.2 The animal health products industry

1.2.1 Leading companies in the animal health sector

1.2.1.1 Industry sales rankings in 2006

1.2.1.2 Industry sales rankings in 2007

1.2.2 Industry profit levels

1.3 Currencies and exchange rates used in this report

SECTION A ANIMAL HEALTH MAJORS

CHAPTER 2 ALPHARMA

2.1 Company background

2.2 Animal health sales and operating profit

2.2.1 2005 performance

2.2.2 2006 performance

2.2.3 Interim 2007 performance

2.3 Geography of the business

2.3.1 US

2.3.2 International markets

2.4 Product portfolio

2.4.1 Antibiotics

2.4.2 Anticoccidials

2.4.3 Antibacterials

2.4.4 Other products

2.5 R&D

2.6 Strategy

2.7 Prospects

CHAPTER 3 BAYER

3.1 Company background

3.2 Animal health sales and earnings

3.2.1 2005 performance

3.2.2 2006 performance

3.2.3 Interim 2007 performance

3.3 Geography of the business

3.3.1 North America

3.3.2 Europe

3.3.3 Asia/Pacific

3.3.4 Latin America

3.4 Product portfolio

3.4.1 Antiparasitics

3.4.2 Antimicrobials

3.4.3 Other products

3.5 R&D

3.6 Strategy

3.7 Prospects

CHAPTER 4 BOEHRINGER INGELHEIM

4.1 Company background

4.2 Animal health sales

4.2.1 2005 performance

4.2.2 2006 performance

4.2.3 Interim 2007 performance

4.3 Geography of the business

4.3.1 Europe

4.3.2 North America

4.3.3 Other markets

4.4 Product portfolio

4.4.1 Pharmaceuticals

4.4.2 Biologicals

4.4.3 Other products

4.5 R&D

4.6 Strategy

4.7 Prospects

CHAPTER 5 CEVA

5.1 Company background

5.2 Animal health sales and earnings

5.2.1 2005 performance

5.2.2 2006 performance

5.2.3 Interim 2007 performance

5.3 Geography of the business

5.3.1 Europe

5.3.2 North America

5.3.3 International markets

5.4 Product portfolio

5.4.1 Companion animal products

5.4.2 Reproductive controls

5.4.3 Anti-infectives

5.4.4 Vaccines

5.4.5 Others

5.5 R&D

5.6 Strategy

5.7 Prospects

CHAPTER 6 ELANCO

6.1 Company background

6.2 Animal health sales and operating income

6.2.1 2005 performance

6.2.2 2006 performance

6.2.3 Interim 2007 performance

6.3 Geography of the business

6.3.1 US

6.3.2 International markets

6.4 Product portfolio

6.4.1 Tylosin

6.4.2 Tilmicosin

6.4.3 Monensin

6.4.4 Avilamycin

6.4.5 Ractopamine

6.4.6 Other products

6.5 R&D

6.6 Strategy

6.7 Prospects

CHAPTER 7 FORT DODGE

7.1 Company background

7.2 Animal health sales and operating profit

7.2.1 2005 performance

7.2.2 2006 performance

7.2.3 Interim 2007 performance

7.3 Geography of the business

7.3.1 US

7.3.2 International markets

7.4 Product portfolio

7.4.1 Biologicals

7.4.2 Antiparasitics

7.4.3 Other pharmaceuticals

7.5 R&D

7.6 Strategy

7.7 Prospects

CHAPTER 8 MERIAL

8.1 Company background

8.2 Animal health sales and operating income

8.2.1 2005 performance

8.2.2 2006 performance

8.2.3 Interim 2007 performance

8.3 Geography of the business

8.3.1 US

8.3.2 Europe

8.3.3 International

8.4 Product portfolio

8.4.1 Avermectins

8.4.2 Fipronil

8.4.3 Biologicals

8.4.4 Other products

8.5 R&D

8.6 Strategy

8.7 Prospects

CHAPTER 9 NOVARTIS

9.1 Company background

9.2 Animal health sales and operating profit

9.2.1 2005 performance

9.2.2 2006 performance

9.2.3 Interim 2007 performance

9.3 Geography of the business

9.3.1 North America

9.3.2 Europe

9.3.3 Other markets

9.4 Product portfolio

9.4.1 Antiparasitics

9.4.2 Anti-infectives

9.4.3 Other pharmaceuticals

9.4.4 Vaccines

9.5 R&D

9.6 Strategy

9.7 Prospects

CHAPTER 10 PFIZER

10.1 Company background

10.2 Animal health sales and operating profit

10.2.1 2005 performance

10.2.2 2006 performance

10.2.3 Interim 2007 performance

10.3 Geography of the business

10.3.1 US

10.3.2 International markets

10.4 Product portfolio

10.4.1 Anti-infectives

10.4.2 Antiparasitics

10.4.3 Vaccines

10.4.4 Other pharmaceuticals

10.5 R&D

10.6 Strategy

10.7 Prospects

CHAPTER 11 SCHERING-PLOUGH

11.1 Company background

11.2 Animal health sales and earnings

11.2.1 2005 performance

11.2.2 2006 performance

11.2.3 Interim 2007 performance

11.3 Geography of the business

11.3.1 US

11.3.2 Europe

11.3.3 Other markets

11.4 Product portfolio

11.4.1 Vaccines

11.4.2 Anti-infectives

11.4.3 Antiparasitics

11.4.4 Other products

11.5 R&D

11.6 Strategy

11.7 Prospects

CHAPTER 12 VETOQUINOL

12.1 Company background

12.2 Animal health sales and operating profit

12.2.1 2005 performance

12.2.2 2006 performance

12.2.3 Interim 2007 performance

12.3 Geography of the business

12.3.1 Europe

12.3.2 North America

12.3.3 Other markets

12.4 Product portfolio

12.4.1 Anti-infectives

12.4.2 Other pharmaceuticals

12.4.3 Other products

12.5 R&D

12.6 Strategy

12.7 Prospects

CHAPTER 13 VIRBAC

13.1 Company background

13.2 Animal health sales and operating profit

13.2.1 2005 performance

13.2.2 2006 performance

13.2.3 Interim 2007 performance

13.3 Geography of the business

13.3.1 Europe

13.3.2 North America

13.3.3 Other markets

13.4 Product portfolio

13.4.1 Antiparasitics

13.4.2 Anti-infectives

13.4.3 Biologicals

13.4.4 Other products

13.5 R&D

13.6 Strategy

13.7 Prospects

SECTION B OTHER SIGNIFICANT PLAYERS

CHAPTER 14 CENTRAL GARDEN & PET

14.1 Company background

14.2 Animal health business

14.3 Geography of the business

14.4 Product portfolio

14.5 Strategy

14.6 Prospects

CHAPTER 15 CHINA ANIMAL HUSBANDRY INDUSTRY CO.

15.1 Company background

15.2 Animal health sales

15.3 Geography of the business

15.4 Product portfolio

15.5 Strategy

15.6 Prospects

CHAPTER 16 DAINIPPON SUMITOMO PHARMA

16.1 Company background

16.2 Animal health sales

16.3 Geography of the business

16.4 Product portfolio

16.5 Strategy

16.6 Prospects

CHAPTER 17 HESKA

17.1 Company background

17.2 Animal health sales and operating profit

17.3 Geography of the business

17.4 Product portfolio

17.5 Strategy

17.6 Prospects

CHAPTER 18 IDEXX

18.1 Company background

18.2 Animal health sales

18.3 Geography of the business

18.4 Product portfolio

18.5 Strategy

18.6 Prospects

CHAPTER 19 JANSSEN

19.1 Company background

19.2 Animal health sales

19.3 Geography of the business

19.4 Product portfolio

19.5 Strategy

19.6 Prospects

CHAPTER 20 KYORITSU SEIYAKU

20.1 Company background

20.2 Geography of the business

20.3 Product portfolio

20.4 Strategy

20.5 Prospects

CHAPTER 21 MEIJI SEIKA

21.1 Company background

21.2 Animal health sales

21.3 Geography of the business

21.4 Product portfolio

21.5 Strategy

21.6 Prospects

CHAPTER 22 MONSANTO

22.1 Company background

22.2 Animal health business

22.3 Geography of the business

22.4 Product portfolio

22.5 Strategy

22.6 Prospects

CHAPTER 23 NIPPON ZENYAKU

23.1 Animal health sales

23.2 Geography of the business

23.3 Product portfolio

23.4 Strategy

23.5 Prospects

CHAPTER 24 NORBROOK

24.1 Company background

24.2 Animal health sales

24.3 Geography of the business

24.4 Product portfolio

24.5 Strategy

24.6 Prospects

CHAPTER 25 ORION

25.1 Company background

25.2 Animal health business

25.3 Geography of the business

25.4 Product portfolio

25.5 Strategy

25.6 Prospects

CHAPTER 26 PHIBRO

26.1 Company background

26.2 Animal health business

26.3 Geography of the business

26.4 Product portfolio

26.5 Strategy

26.6 Prospects

CHAPTER 27 TEVA

27.1 Company background

27.2 Animal health sales

27.3 Geography of the business

27.4 Product portfolio

27.5 Strategy

27.6 Prospects

LIST OF TABLES

Table 1.1: Geography of the world market, 2006

Table 1.2: World market structure by product category, 2006

Table 1.3: World market structure by species, 2006

Table 1.4: Animal health industry sales rankings, 1996 and 2006

Table 1.5: Animal health company sales rankings,

Table 1.6: Animal health company sales ranking forecasts, 2007

Table 1.7: Animal health company profit rankings, 2006

Table 1.8: Animal health company profit margins, 2002-2006

Table 2.1: Alpharma's revenues by division, 2006

Table 2.2: Alpharma animal health sales, 2002-

Table 2.3: Alpharma animal health income and margins, 2002-

Table 2.4: Alpharma first half sales, 2006 and 2007

Table 2.5: Alpharma animal health revenues by region,

Table 2.6: Alpharma's major product sales, 2006

Table 3.1: Bayer sales by operating segment,

Table 3.2: Bayer animal health sales, 2002-2006

Table 3.3: Bayer animal health earnings and margins

Table 3.4: Bayer's first half sales, 2006-

Table 3.5: Bayer animal health sales by region, 2006

Table 4.1: Boehringer Ingelheim sales by business area, 2006

Table 4.2: BIV sales, 2002-2006

Table 4.3: BIV sales by region,

Table 4.4: Sales of major BIV brands,

Table 5.1: Ceva animal health sales, 2002-

Table 5.2: Ceva earnings and operating margins, 2002-2006

Table 5.3: Acquisitions completed by Ceva since

Table 6.1: Elanco's animal health sales, 2002-2006

Table 6.2: Elanco's operating income and margin, 2002-2006

Table 6.3: Elanco's interim 2007 sales performance

Table 6.4: Elanco's US/international sales split, 2002-2006

Table 7.1: Wyeth sales by operating segment,

Table 7.2: Fort Dodge animal health sales, 2002-

Table 7.3: Fort Dodge operating income and margins, 2002-2006

Table 7.4: Fort Dodge first half sales, 2006-2007

Table 7.5: Fort Dodge US/international sales split, 2002-

Table 7.6: Fort Dodge sales by species, 2006

Table 8.1: Merial animal health sales, 2002-2006

Table 8.2: Merial first half animal health sales, 2006 and 2007

Table 8.3: Merial sales by product category,

Table 8.4: Merial's avermectin revenues, 2002-2006

Table 8.5: Leading formulations in the Merial ivermectin range

Table 8.6: Fipronil sales, 2002-

Table 9.1: Novartis sales by operating segment,

Table 9.2: Novartis animal health sales, 2002-

Table 9.3: Novartis animal health sales by region,

Table 9.4: Novartis animal health sales by product segment, 2006

Table 10.1: Pfizer sales by operating segment, 2006

Table 10.2: Pfizer animal health sales, 2002-

Table 10.3: Pfizer animal health earnings and margins, 2002-

Table 10.4: Pfizer first half animal health sales, 2006 and

Table 10.5: Pfizer's US/international sales split, 2005 and

Table 10.6: Pfizer animal health sales by species segment, 2005 and 2006

Table 10.7: Recent additions to the Pfizer anti-infectives range

Table 11.1: Schering-Plough sales by business sector,

Table 11.2: SPAH sales, 2002-

Table 11.3: SPAH earnings and divisional margins, 2002-2006

Table 11.4: SPAH first half sales, 2006 and 2007

Table 11.5: SPAH's US/international sales split, 2005 and 2006

Table 11.6: Geography of the expanded SPAH business

Table 12.1: Vétoquinol sales, 2002-2006

Table 12.2: Vétoquinol's first-half sales, 2006 and

Table 12.3: Vétoquinol sales by region,

Table 12.4: Vétoquinol's key acquisitions

Table 12.5: Vétoquinol sales by product category, 2006

Table 13.1: Virbac animal health sales, 2002-

Table 13.2: Virbac first half sales, 2006 and 2007

Table 13.3: Virbac sales by region, 2006

Table 13.4: Virbac sales by product segment,

Table 14.1: CG&P sales by operating segment, 2006

Table 15.1: CAHIC financial results, 2004-

Table 15.2: CAHIC sales by product segment, 2006

Table 16.1: DSP sales by operating segment, fiscal

Table 16.2: DSP Animal Science sales, 2003-

Table 16.3: DSP Animal Science sales by product segment

Table 17.1: Heska earnings and income, 2002-

Table 17.2: Heska revenues, 2002-

Table 17.3: Heska revenues by geographic area

Table 17.4: Heska revenues by product category

Table 18.1: Idexx sales by operating segment, 2006

Table 18.2: Idexx sales by region, 2006

Table 18.3: Idexx companion animal rapid diagnostic assay sales

Table 18.4: Idexx veterinary pharmaceutical sales

Table 20.1: Kyoritsu Seiyaku animal health sales and growth rates

Table 22.1: Monsanto sales by operating segment, 2006

Table 23.1: NZK sales by product sector

Table 24.1: Norbrook sales and earnings, 2002-2006

Table 25.1: Orion sales by business sector, 2006

Table 25.2: Orion's veterinary sedative sales, 2002-2006

Table 27.1: Teva sales by operating segment, 2006